University of Cologne

Cologne 50937

4 studies enrolling now · 16 studies all time

What they study most

Acute Kidney Injury, Age-Related Maculopathy, Aneurysm, Brain, Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T), CACNA1A, Chronic Kidney Disease(CKD), Enterococcal Bacteremia, Epidemiology, Episodic Ataxia Type 2, Extranodal Extension, Familial Hemiplegic Migraine-1

Studies at this site

• Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset — Recruiting now
• Pivotal Study of N-acetyl-L-leucine for CACNA1A — Starting soon
• Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment — Enrolling by invitation
• Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 — Enrolling by invitation
• Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — Running, not enrolling
• Setrusumab vs Placebo for Osteogenesis Imperfecta — Running, not enrolling
• A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T) — Running, not enrolling
• International Guillain-Barré Syndrome Outcome Study — Completed
• Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer — Completed
• Romidepsin Plus 3BNC117 Phase 2a Study — Completed
• Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms — Status unconfirmed
• VENOUS: A Translational Study of Enterococcal Bacteremia — Status unconfirmed
• A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 — Completed
• A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 — Completed
• A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy — Completed
• Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis — Paused